| Cat.No. | Name | Information |
|---|---|---|
| M9428 | MRTX849 (Adagrasib) | MRTX849 (Adagrasib) is a potent, highly selective, oral available KRAS G12C inhibitor. |
| M9356 | AMG-510 (Sotorasib) | AMG-510 (Sotorasib) is a potent KRAS G12C covalent inhibitor. |
| M8999 | CCG-1423 | CCG-1423 is a novel specific inhibitor of RhoA transcriptional signaling. |
| M6282 | NSC 23766 | NSC 23766 is an inhibitor of Rac GTPase targeting Rac activation by guanine nucleotide exchange factors (GEFs) with IC50 of ~50 μM in a cell-free assay; does not inhibit the closely related targets, Cdc42 or RhoA. |
| M2562 | ZCL278 | ZCL278 is a selective Cdc42 GTPase inhibitor with Kd of 11.4 μM. |
| M56323 | Rasarfin | Rasarfin is a dual Ras and ARF6 inhibitor. |
| M56321 | Z62954982 | Z62954982 (ZINC08010136) is a potent, selective and cell-permeable Rac1 (IC50=12 μM) inhibitor that is 4 times more effective than NSC23766 (IC50=50 μM). |
| M55573 | ACBI3 | ACBI3 (compound 7) is a pan-KRAS degrader. ACBI3 achieves in vivo degradation of oncogenic KRAS. |
| M55018 | RMC-9805 | RMC-9805 (KRAS G12D inhibitor 18) is a first-in-class, orally active KRAS G12D inhibitor. RMC-9805 (KRAS G12D inhibitor 18) inhibits RAS signaling and induces apoptosis in KRAS G12D mutant cancer cells. |
| M54858 | RMC-7977 | RMC-7977 is a highly selective, reversible, tri-complex RAS inhibitor of the active (GTP-bound) forms of KRAS, HRAS, and NRAS, with affinity for both mutant and wild type (WT) variants. RMC-7977 demonstrated potent activity against RAS-addicted tumours carrying various RAS genotypes, particularly against cancer models with KRAS codon 12 mutations (KRASG12X). |
| M40832 | RAS-IN-2 | RAS-IN-2 (RMC-6236) is a potent pan-KRAS inhibitor targeting activation-state KRAS for cancer-related studies. |
| M40563 | AZD4747 | AZD4747 is an orally active, potent, and selective KRAS G12C inhibitor that crosses the blood-brain barrier and can be used in studies related to solid tumors with KRAS G12C mutations. |
| M40562 | LUNA18 | LUNA18 is an orally active RAS cyclic peptide inhibitor that selectively targets, binds and inhibits Ras, thereby inhibiting Ras-dependent signaling and ultimately suppressing the proliferation of Ras-overexpressing tumor cells. It can be used in studies related to solid tumors. |
| M40499 | BI-2865 | BI-2865 is a non-covalent pan-KRAS inhibitor that binds to KRAS WT, G12C, G12D, G12V, and G13D mutants with Kd values of 6.9 nM, 4.5 nM, 32 nM, 26 nM, and 4.3 nM, respectively.It can be used in studies related to KRAS mutant tumors. |
| M29707 | Garsorasib | Garsorasib is a potent inhibitor of KRAS G12C with an IC50 of 10 nM. Garsorasib has the potential for the research of various cancer such as pancreatic cancer, endometrial cancer, colorectal cancer, or lung cancer (non-small cell lung cancer). |
| M27747 | AZA1 | AZA1 is a potent dual inhibitor of Rac1 and Cdc42. AZA1 induces prostate cancer cells apoptosis and inhibits prostate cancer cells proliferation, migration and invasion. |
| M25612 | RMC-6291 | |
| M21533 | BI-0474 | BI-0474 is a covalent KRASG12C inhibitor. The IC50 value for GDP-KRAS::SOS1 protein-protein interaction was 7.0 nM. BI-0474 also showed better antitumor activity in non-small cell lung cancer xenograft models. |
| M20741 | Antineoplaston A10 | Antineoplaston A10 is a naturally occurring substance in the human body that that can be potentially used for the treatment of glioma, lymphoma, astrocytoma and breast cancer. The main ingredient active of antineoplaston A10 (Phenylacetylglutamine, PG) inhibits RAS and promotes apoptosis. |
| M20013 | MRTX0902 | MRTX0902 is an oral brain penetrating SOS1:KRAS protein-protein interaction inhibitor with an IC50 of 46 nM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
